Abegail Unico
Primary Care · Royal Palm Beach, FLNPI 1235660960
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 358 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by AstraZeneca at 26.5% of the total. Among primary care clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 358 payments — averaging $21.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$1K
- Pfizer$968
- Lilly USA, LLC$745
- Novo Nordisk$687
- Amgen$486
- plus $2K from 24 others
What the payments were for
- Food & beverage$7,49299%
- Education$1071%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 49 | $2,011 |
| AbbVie(2 entities) | 70 | $1,037 |
| Pfizer | 48 | $968 |
| Lilly USA, LLC | 48 | $745 |
| Novo Nordisk | 43 | $687 |
| Amgen | 24 | $486 |
| Exact Sciences | 12 | $281 |
| Astellas Pharma US Inc | 7 | $206 |
| GSK | 12 | $199 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $140 |
| Bayer | 2 | $138 |
| Eisai Inc. | 2 | $134 |
| Abbott | 7 | $127 |
| Johnson & Johnson | 4 | $62 |
| Boehringer Ingelheim | 3 | $56 |
| Jazz Pharmaceuticals Inc. | 3 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $31 |
| Dexcom, Inc. | 2 | $28 |
| IBSA Pharma Inc. | 1 | $24 |
| Gilead | 1 | $23 |
| Radius Health, Inc. | 1 | $23 |
| Optinose US, Inc. | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Novartis | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,598 in reported general payments places this provider in the 95th percentile of 725 primary care providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $44,051 |
| OzempicSemaglutide | 40 | $37,899 |
| TrulicityDulaglutide | 21 | $36,630 |
| MounjaroTirzepatide | 33 | $33,932 |
| LinzessLinaclotide | 23 | $21,371 |
| ProliaDenosumab | 11 | $19,264 |
| FarxigaDapagliflozin Propanediol | 13 | $16,250 |
| JardianceEmpagliflozin | 11 | $14,621 |
| SynthroidLevothyroxine Sodium | 28 | $3,167 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 90 | $2,485 |
| Rosuvastatin Calcium | 144 | $1,360 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 15 | $1,261 |
| Atorvastatin Calcium | 204 | $1,129 |
| Amlodipine Besylate | 224 | $905 |
| Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide | 29 | $837 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $745 | $70,56254 claims |
| PfizerEliquis | $968 | $44,05142 claims |
| Novo NordiskOzempic | $687 | $37,89940 claims |
| AbbVieLinzess, Synthroid | $1,037 | $24,53851 claims |
| AmgenProlia | $486 | $19,26411 claims |
| AstraZenecaFarxiga | $2,011 | $16,25013 claims |
| Boehringer IngelheimJardiance | $56 | $14,62111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 725 primary care providers in Florida.
Other primary care in Royal Palm Beach
- Paul ChanOrlando$447K
- Jenny WestPensacola$80K
- Railet RodriguezAltamonte Springs$14K
- Kevin HanawayFort Lauderdale$12K
- Kelly ChewningAlachua$11K
- Yolanda PalmeroSaint Cloud$11K
- Erica ClarkCitrus Springs$11K
- Michelle SelvaggiLakewood Ranch$10K
- Kristen DeasonTallahassee$10K
- Robert PerriPalm Coast$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.